This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thompson CA et al. (2003) Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8: 474–487
Braga-Basaria M et al. (2006) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24: 3979–3983
Keating NL et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456
Sato N et al. (1996) Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58: 139–146
Akakura E et al. (1993) Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and prostate-specific antigen. Cancer 71: 2782–2790
de Leval J et al. (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1: 163–171
Tunn UW (online 2007) Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507 [http://www.abstracts2view.com/aua_archive/view.php?nu=200791183] (accessed 17 June 2008)
Miller K et al. (2007) Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract]. J Clin Oncol 25 (Suppl 18S): 5015
Calais da Silva FM et al. (2006) Phase III study of intermittent MAB versus continuous MAB [abstract]. J Clin Oncol 24 (Suppl 18S): 4513
Prostate Cancer Trialists' Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 335: 1491–1498
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Randomized clinical trials comparing intermittent and continuous androgen deprivation therapy in prostate cancer. (DOC 30 kb)
Rights and permissions
About this article
Cite this article
Seruga, B., Tannock, I. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Rev Clin Oncol 5, 574–576 (2008). https://doi.org/10.1038/ncponc1180
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1180
- Springer Nature Limited
This article is cited by
-
Tumor metastasis: moving new biological insights into the clinic
Nature Medicine (2013)
-
Drug rechallenge and treatment beyond progression—implications for drug resistance
Nature Reviews Clinical Oncology (2013)
-
Stochastic dynamics of leukemic cells under an intermittent targeted therapy
Theory in Biosciences (2011)
-
Metronomic chemotherapy: new rationale for new directions
Nature Reviews Clinical Oncology (2010)
-
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
Nature Clinical Practice Urology (2009)